



Certificate of Analysis

www.tocris.com

Product Name: Maraviroc Catalog No.: 3756 Batch No.: 1

CAS Number: 376348-65-1

IUPAC Name: 4,4-Difluoro-*N*-{(1*S*)-3-[3-(3-isopropyl- 5-methyl-4*H*-1,2,4-triazol-4-yl)- 8-azabicyclo[3.2.1]oct-8-yl]-1- phenylpropyl}

cyclohexanecarboxamide

1. PHYSICAL AND CHEMICAL PROPERTIES

Batch Molecular Formula: $C_{29}H_{41}F_2N_5O$

Batch Molecular Weight: 513.67 **Physical Appearance:** White solid

Solubility: DMSO to 75 mM

ethanol to 100 mM

Storage: Store at +4°C

Batch Molecular Structure:

2. ANALYTICAL DATA

HPLC: Shows 100% purity

¹H NMR: Consistent with structure Mass Spectrum: Consistent with structure

Optical Rotation: $[\alpha]_D = -26.6$ (Concentration = 1, Solvent = Methanol)

Microanalysis: Carbon Hydrogen Nitrogen

Theoretical 67.81 8.05 13.63 Found 67.91 8.03 13.75



Product Information

Print Date: May 11th 2016 **WWW.tocris.com**

Product Name: Maraviroc Catalog No.: 3756 Batch No.: 1

CAS Number: 376348-65-1

IUPAC Name: 4,4-Difluoro-*N*-{(1*S*)-3-[3-(3-isopropyl- 5-methyl-4*H*-1,2,4-triazol-4-yl)- 8-azabicyclo[3.2.1]oct-8-yl]-1- phenylpropyl}

cyclohexanecarboxamide

Description:


Selective CCR5 antagonist; displays potent anti-HIV-1 activity. Prevents the interaction of HIV-1 gp120 and CCR5 (IC $_{50}$ = 6.4 nM), inhibiting HIV-1 entry. Exhibits antinociceptive effects in a rat model of neuropathic pain. Also inhibits CCL3 (MIP-1 α) binding to CCR5. Orally bioavailable.

Physical and Chemical Properties:

Batch Molecular Formula: $C_{29}H_{41}F_2N_5O$ Batch Molecular Weight: 513.67 Physical Appearance: White solid

Minimum Purity: >99%

Batch Molecular Structure:



Storage: Store at +4°C

Solubility & Usage Info:

DMSO to 75 mM ethanol to 100 mM

Stability and Solubility Advice:

Some solutions can be difficult to obtain and can be encouraged by rapid stirring, sonication or gentle warming (in a 45-60°C water bath).

Information concerning product stability, particularly in solution, has rarely been reported and in most cases we can only offer a general guide. Our standard recommendations are:

SOLIDS: Provided storage is as stated on the product label and the vial is kept tightly sealed, the product can be stored for up to 6 months from date of receipt.

SOLUTIONS: We recommend that stock solutions, once prepared, are stored aliquoted in tightly sealed vials at -20°C or below and used within 1 month. Wherever possible solutions should be made up and used on the same day.

References:

Piotrowska *et al* (2016) Maraviroc reduces neuropathic pain through polarization of microglia and astroglia - Evidence from *in vivo* and *in vitro* studies. Neuropharmacology **S0028-3908** 30164. PMID: 27117708.

Garcia-Perez et al (2011) New insights into the mechanisms whereby low molecular weight CCR5 ligands inhibit HIV-1 infection. J.Biol.Chem. 286 4978. PMID: 21118814.

Kuritzkes et al (2008) Fresh from the pipeline - maraviroc. Nat.Rev.Drug Discov. 715.

Dorr *et al* (2005) Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob.Agents Chemother. *49* 4721. PMID: 16251317.

Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use